T HE occurrence of inyocardial inifaretion and embolic incidents in patients with ischemic heart disease after cessation of anticoagulant therapy is well recognized.1-6 Likewise, the recurrence of intermittent ischemic attacks in the carotid and vertebro-basilar territory when anticoagulant treatment has been stopped has been described.7 These experiences have led to the suggestion that following the cessation of anticoagulant therapy there is a "rebound phenomenon" during which further clinical ineidents are more likely to occur.
Ascertaining whether such a phenomenon exists meets with two difficulties. The first is that if anticoagulant therapy is effectively suppressing a continuing tendency to thromboembolism, stopping therapy allows the tendency to reassert itself; hence there is likely to be a recurrence of clinical incidents. It has indeed been snggested that the "rebound phenomenon " is simply "'a return to the status quo ante" and not a rebound in the usual sense.8 But The results are set out in table 1. During the period on therapy, which comprised 2,399 patient-months, there were 25 nonfatal cerebrovascular incidents, giving a rate of 1.0 per 100 patient-months. At this rate the expected number of incidents during the first 3 months after the drug was finally stopped was 1.9. The observed incidence during this period was 6 (3.2 per 100 patient-months) (table 1). The probability that a difference as large as that between the expected and observed ineidence would occur by chance may be obtained from the Poisson distribution and is about one in 50. The observed incidence during the fourth to twelfth month after stopping therapy was 2.0 per 100 patient-months. There is therefore good evidence that during the 3 months after treatment was stopped there was an increased incidence of nonfatal cerebrovascular episodes and that the increase was beyond what might be expected as a result of chance variation in the incidence rate.
The problem as to whether this increased number of incidents following cessation of therapy might be attributable to the natural progress of the disease was next examined by comparing the incidence rate over various periods (table 2) . This shows that there was no increased incidence in four periods each of 6 months' duration prior to the stopping of treatment. Similarly, although the ineidence over the whole year after treatment was stopped was higher than at any time during therapy, it was less in the second 6 months than it was in the first. Moreover, the average rate of occurrence of nonfatal accidents was much less in the second 6 months after cessation of therapy than it was in' the 3 months immediately after stopping therapy. There is therefore nothing to suggest that the increased incidence in the first 3 months after therapy was stopped was due to the natural progress of the disease.
During the time these patients were under treatment there were seven temporary interruptions of therapy of less than 28 days because of hemorrhage; none of these patients experienced a cerebrovascular accident within the succeeding 3 months. There were four instances in which treatment was permanently discontinued because of hemorrhage and, again, there were no cerebrovascular accidents within the next 3 months. There were 24 interruptions of therapy for reasons other than hemorrhage (two of 4 weeks, one of 3 weeks, five of 2 weeks, seven of 1 week, and nine of Circulation, Volume XXVIII, September 196S REBOUND PHENOMENA AFTER ANTICOAGULANTS 1 to 5 days); one of these was followed by a cerebrovascular incident, which occurred 32 days after resumption of treatment. One patient died of a myocardial infaretion 19 days after an interruption of therapy of 9 days' duration for dental extractions. Three patients died while therapy was being reduced, one of left ventricular failure, one of cerebral hemorrhage proved at autopsy, and one of a myocardial infaret.
Discussion
The value of anticoagulant therapy in abolishing intermittent cerebrovascular isehemic attacks is well established.7 13, 14 The hope was that therapy would be of equal value in patients who had recovered from a major cerebrovascular accident -by preventing recurrences. This proved not to be the case.', 12'15' 16 The present series did, however, fortuitously provide a group of patients in whom therapy had been ineffective and from whom it was to be withdrawn. The possibility that any increase after therapy was due to the restoration to normal levels of a suppressed thromboembolic tendency was eliminated, for there was no evidence that this tendency had been suppressed by the therapy; the incidence of nonfatal cerebrovascular episodes in these patients during therapy did not differ from that in a control group chosen by random selection and shown to be constituted similarly in all material respects. Thus the difficulty innate in the study of the "rebound phenomenon" in any group of patients in whom anticoagulant therapy had been effective was avoided.
The value of a study of this kind depends largely upon the accuracy with which further cerebrovascular accidents are diagnosed and recorded. It was for this reason that the assessment was based on the incidence of nonfatal cerebrovascular accidents and fatal accidents were not included. The accuracy with which the cause of a fatal stroke can be determined clinically is not high,17 and this is especially so if the patient cannot be seen personally. The possibility that fatal cerebrovascular accidents due to intracerebral hemorrhage might be attributed to the "rebound Circulation, Volume XXVIII, September 1963 phenomenon " was therefore considerable; this source of inaccuracy was avoided by confining attention to the nonfatal accidents in which the possibility of a small hemorrhage mimicking a thrombo-embolic incident is less. Complete records were obtained by ensuring that the patients were seen regularly at intervals of 4 weeks or less.
When therapy was withdrawn from these patients, even by gradual reduction of dosage over a minimum of 4 weeks, there was an increased incidence of nonfatal cerebrovascular accidents in the first 3 months after cessation of therapy, an increase that is likely to have occurred by chance only 1 in 50 times. Subsequently, the incidence rate fell, though not to pretreatment levels. The influence of a possible seasonal factor in the incidence of cerebrovascular accidents cannot be entertained as the patients were withdrawn from therapy throughout the year. Nor can the natural progress of the disease be held responsible, as comparison of the incidence rate over 6-monthly periods showed no progressive increase. The observation therefore provides strong evidence for the existence of a true "rebound phenomenon. " Despite the fact that anticoagulants did not influence the incidence of cerebrovascular accidents, withdrawal of therapy did produce an increased incidence, which might well be attributed to a hypercoagulable state.
The suggestion that the "rebound phenomenon" is more likely to appear when treatment is stopped because of hemorrhage than as part of a planned withdrawal" finds no support in the present study, though the number of temporary and permanent stoppages for hemor- 
